The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who are at high risk of becoming seriously ill. It will also require manufacturers to conduct clinical trials to show whether the vaccines benefit healthy younger adults and children.

The change marks a shift in the Food and Drug Administration’s policy on approving COVID-19 vaccines, which the new commissioner described as a “one-size-fits-all regulatory framework.”

The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to green-lighting shots that have been recommended broadly to the public.